Special Project in Non-Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer Canada (PCC) has offered investigator-initiated Special Project in Non-Metastatic Castrate Resistant Prostate Cancer (NM-CRPC). This request for applications (RFA) solicited proposals from groups interested in combining various real world data sources (i.e. detailed chart review at prostate cancer centres with health administrative databases) to obtain high quality epidemiological data, outcomes and costs among the population of prostate cancer patients in at least two provinces in Canada that together represent greater than 50% of the population.
 
The key objectives were:
  • to obtain prevalence, incidence and survival probability estimates of prostate cancer, stratified by age and year of diagnosis from provincial cancer registries;
  • to identify pathways leading to and factors associated with the target condition (NM-CRPC);
  • to estimate annual incidence and prevalence of NM-CRPC, stratified probability of developing NM-CRPC and transition probabilities that characterize the prognosis from NM-CRPC to metastasis and end-of-life;
  • to estimate health care resource use and costs for health states in the recurrent disease model.
 
Award amount: up to $450,000 over 2 years

 




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Prostate Cancer Canada Partners with Screw Cancer™

TORONTO, ON - Starting today, you can screw cancer and give hope in your local community by purchasing the Screw Cancer™ screwdriver in support of Prostate Cancer Canada.
More

Indy Cycling Challenge at Exhibition Place Announced to Support Prostate Cancer Canada

TORONTO (January 24, 2017) – Cycling enthusiasts have the opportunity to band together for a great cause while experiencing the Honda Indy Toronto like never before.
More

BRCA2 gene implicated in rare but lethal prostate cancer

January 9, 2017 – TORONTO, ON – Canadian scientists have discovered a link between an inherited mutation in the BRCA2 gene and a deadly form of prostate cancer.
More


Click here for news archive